Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study

Published:October 11, 2022DOI:



      Extraintestinal manifestations (EIM) are associated with diminished quality of life. The efficacy of Ustekinumab and vedolizumab for EIM treatment is not well established. The aim was to compare the effectiveness of ustekinumab and vedolizumab for treatment of EIM in IBD.


      We included IBD patients treated with vedolizumab or ustekinumab in the Gastroenterology department, Sheba Medical Center, for up to 52 weeks between 2015 and 2021. Patients with active EIM before treatment initiation were included.


      111 patients were included. 53 patients (48%) were treated with ustekinumab; 88% (n-99) had CD. The most common EIM was arthralgia (95/111, 84%). Patients treated with ustekinumab were more likely to be anti-TNF experienced (n-51/53 [96%] compared with vedolizumab n = 36/58 [62%], p < 0.001).
      Clinical response of EIM at week 52 was achieved in 36% of patients treated with ustekinumab (n-18/50) and 34% of patients (n-19/54) treated with vedolizumab, with no statistically significant difference (p = 0.9). No statistical significance was achieved for patients presented with arthralgia. Clinical response of arthralgia at week 52 was seen in 34% (n-19/55) and 36% (n-18/46) of the patients treated with vedolizumab and ustekinumab, respectively, (p = 0.3).


      In this study, no difference was found between vedolizumab and ustekinumab regarding their effect on EIM in IBD patients for up to 52 weeks.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rogler G.
        • Singh A.
        • Kavanaugh A.
        • Rubin D.T.
        Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management.
        Gastroenterology. 2021; 161: 1118-1132
        • Vidal A.
        • Gómez-Gil E.
        • Sans M.
        • et al.
        Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality.
        Inflamm Bowel Dis. 2008; 14: 977-983
        • Derfalvi B.
        • Boros K.K.
        • Szabo D.
        • et al.
        Joint involvement, disease activity and quality of life in pediatric Crohn's disease – a cross-sectional study.
        Pediatr Rheumatol. 2022; 20: 6
        • Vavricka S.R.
        • Schoepfer A.
        • Scharl M.
        • Lakatos P.L.
        • Navarini A.
        • Rogler G.
        Extraintestinal manifestations of inflammatory bowel disease.
        Inflamm Bowel Dis. 2015; 21: 1982-1992
        • Bhagat S.
        • Das KM.
        A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody.
        Gastroenterology. 1994; 107: 103-108
        • Liefferinckx C.
        • Verstockt B.
        • Gils A.
        • et al.
        Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies: a national cohort study.
        J Crohn's Colitis. 2019; 13: 1401-1409
        • Guillo L.
        • D'Amico F.
        • Danese S.
        • Peyrin-Biroulet L.
        Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
        J Crohn's Colitis. 2021; 15: 1236-1243
        • Biemans V.B.
        • van der Meulen-de Jong A.E.
        • Van Der Woude C.J.
        • et al.
        Ustekinumab for Crohn's disease: results of the ICC registry, a nationwide prospective observational cohort study.
        J Crohn's Colitis. 2020; 14: 33-45
        • Wyant T.
        • Fedyk E.
        • Abhyankar B.
        An overview of the mechanism of action of the monoclonal antibody vedolizumab.
        J Crohn's Colitis. 2016; 10: 1437-1444
        • Feagan B.G.
        • Rubin D.T.
        • Danese S.
        • et al.
        Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists.
        Clin Gastroenterol Hepatol. 2017; 15: 229-239.e225
        • Dubinsky M.C.
        • Cross R.K.
        • Sandborn W.J.
        • et al.
        Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease.
        Inflamm Bowel Dis. 2018; 24: 1876-1882
        • Hanzel J.
        • Ma C.
        • Casteele N.V.
        • Khanna R.
        • Jairath V.
        • Feagan BG.
        Vedolizumab and extraintestinal manifestations in inflammatory bowel disease.
        Drugs. 2021; 81: 333-347
        • Tadbiri S.
        • Peyrin-Biroulet L.
        • Serrero M.
        • et al.
        Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
        Aliment Pharmacol Ther. 2018; 47: 485-493
        • Macaluso F.S.
        • Orlando R.
        • Fries W.
        • et al.
        The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
        Dig Liver Dis. 2018; 50: 675-681
        • Hedin C.
        • Vavricka S.
        • Stagg A.
        • et al.
        The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy.
        J Crohn's Colitis. 2019; 13: 541-554
        • Gheita T.A.
        • El Gazzar I.I.
        • El-Fishawy H.S.
        • Aboul-Ezz M.A.
        • Kenawy SA.
        Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results.
        Clin Rheumatol. 2014; 33: 713-717
        • Deodhar A.
        • Gensler L.S.
        • Sieper J.
        • et al.
        Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.
        Arthritis Rheumatol. 2019; 71: 258-270
        • Poddubnyy D.
        • Hermann K.-.G.A.
        • Callhoff J.
        • Listing J.
        • Sieper J.
        Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
        Ann Rheum Dis. 2014; 73: 817-823
        • Arepalli S.
        • Rosenbaum JT.
        The use of biologics for uveitis associated with spondyloarthritis.
        Curr Opin Rheumatol. 2019; 31: 349-354
        • de Risi-Pugliese T.
        • Seksik P.
        • Bouaziz J.
        • et al.
        Ustekinumab–Crohn's disease–neutrophilic dermatosis study group. ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: a multicenter retrospective study.
        J Am Acad Dermatol. 2019; 80 (Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum Official journal of the American College of Gastroenterology| ACG. 2012;107:794-795; Nunes G, Patita M, Fernandes V. Refractory pyoderma gangrenosum in a patient with Crohn's disease: complete response to ustekinumab J Crohns Colitis. 2019;13:812-813; Guenova E, Teske A, Fehrenbacher B et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab Archives of dermatology. 2011;147:1203-1205): 781-784
        • Phillips F.M.
        • Verstockt B.
        • Sebastian S.
        • et al.
        Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multicentre case series.
        J Crohn's Colitis. 2020; 14: 1488-1493
        • Fleisher M.
        • Marsal J.
        • Lee S.D.
        • et al.
        Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease.
        Dig Dis Sci. 2018; 63: 825-833
        • Spagnuolo R.
        • Dastoli S.
        • Silvestri M.
        • et al.
        Anti-interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: a case report.
        Dermatol Ther. 2019; 32: e12811